#biopharmaceuticals #Tokyo #Sowanière #Drug Lag

Introduction

In a significant move to tackle the pressing issue known as 'drug lag' in Japan, our company has formed a strategic partnership with Sowanière Inc., a Tokyo-based healthcare consulting firm. This collaboration aims to establish a platform that will assist emerging biopharmaceutical companies in bringing their undeveloped or unapproved drugs to the Japanese market.

Background and Purpose

In recent years, the problem of drug lag has emerged as a critical challenge in pharmaceutical access across Japan. A key factor contributing to this problem is the increasing reluctance of emerging biopharmaceutical companies, mainly from overseas, to pursue development and regulatory approval within the Japanese market.

To address these challenges, our group has set forth a growth strategy termed the